- This event has passed.
Measuring the return from pharmaceutical innovation
May 13 @ 11:00 am – 12:00 pm EDT
Key takeaways
In 2025, R&D productivity across the top 20 biopharma companies showed modest improvement, with projected IRR rising to 7.0%; yet, this gain is heavily concentrated in a narrow set of GLP-1/GIP assets. Beneath the headline, underlying productivity remains challenged, raising important questions about the sustainability of current innovation models. We’ll discuss:
Practical approaches to consider when translating AI investment into measurable R&D productivity gains
Drivers behind recent R&D productivity trends
Key cost and value dynamics shaping pipelines
Strategic priorities to consider when mitigating concentration risk and improve returns
